Turning Discovery Into Health
NIH research is working hard to solve the puzzle of how genes and lifestyle connect to affect our lives and our health. Today, researchers can scan and compare entire genomes very quickly. These studies have already turned up disease “signatures” for type 2 diabetes, heart disorders, prostate cancer, Crohn’s disease, Parkinson’s disease, and age-related macular degeneration. More disease-related gene variants are identified every few months.
The Human Genome Project and thousands of follow-on studies are helping scientists to develop gene-targeted treatments. A poignant example is the case of a woman with lung cancer that had spread to her brain. Diagnosed in 2002, this 44-year-old—a vegetarian who had never smoked—underwent various therapies to stave off what seemed inevitable. Then came a miracle: she learned of a clinical trial testing a new drug, getfitinib, that for some tumors appeared to work as a genetic smart weapon. Her tumor was one of those, and she is alive today because of medical research.
Thanks to NIH-funded basic research that gave us genetic engineering and launched the $40 billion biotech industry, DNA is a household name. Virtually every biomedical research lab and pharmaceutical company throughout the world uses the power of the genomic revolution every day to demystify diseases and find new cures. Within 5 years, the complete DNA instruction book—or whole genome—of an individual will read out for less than $1,000, making genetic analysis a routine part of medical care.
One recent study provides a glimpse of how whole-genome sequencing might eventually be used in the clinic. Scientists evaluated the entire genome of a 40-year-old man to determine his risk for dozens of diseases and his likely response to common drugs. They pinpointed gene variants linked to several diseases in the man’s family, including vascular disease and early sudden death. They also found variants linked to conditions not known to be in his family, such as thyroid and parathyroid diseases. Other gene variants predicted the patient’s likely responses to certain heart medications—information that’s especially relevant since he’s at risk for cardiovascular disorders.
Remarkable advances in the field of pharmacogenomics—how individuals react differently to medicines—indicate that we are moving away from “one-size-fits-all” medicine. Scientists can now identify glitches in our DNA scripts that reveal what drugs may be dangerous—or completely ineffective—for certain people. This information will help doctors calculate precise dosages that match a person’s DNA.
Collectively, research results in this important area of biomedicine are prompting the U.S. Food and Drug Administration (FDA) to consider changing the labeling requirements for important medicines taken by millions of Americans. Already, pharmacogenomic information is contained in about 10% of labels for drugs approved by the FDA to treat a range of conditions including HIV/AIDS, cancer, seizures, and cardiovascular disorders.
Imagine the Future…
- Doctors use a patient’s genetic profile—not just weight or age—to determine the best drug and the optimal dose.
- Testing a drug only in those likely to benefit from it makes clinical trials faster and less expensive, and gets a good drug to market quickly.